



Beke et al. *N Eng J Med*. 2014 Jul 10;371(2):130-9

Clinical Update:

Dupilumab

- ☐ **Moderate-to-severe atopic dermatitis (AD): intractable pruritus associated with sleep disturbance and lower quality-of-life**
- ☐ **T-helper 2 (TH2) inflammation mediates many features of AD**
- ☐ **Regulated by IL-4 and IL-13**

Dupilumab (anti-IL-4R α) blocks the IL-4/IL-13 receptor/ligand system

